Francisco Javier
López Jiménez
Profesor/a Asociado/a en CC. de la Salud
Bruno David
Lourenço Paiva
Publicacions en què col·labora amb Bruno David Lourenço Paiva (6)
2024
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
2022
-
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study
European Journal of Cancer, Vol. 174, pp. 243-250
2016
-
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136
2014
-
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?
Blood, Vol. 124, Núm. 12, pp. 1887-1893
2013
-
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma
New England Journal of Medicine, Vol. 369, Núm. 5, pp. 438-447